An interim analysis can support a planned decision while a trial continues. That flexibility creates dependencies among statistical rules, data readiness, access restrictions, and operational conduct. A decision rule is only useful when the information entering it is appropriate and its use is controlled.
The FDA’s final adaptive-design guidance is the primary reference. The implementation practices below are recommendations for preparing a reviewable interim workflow.
1. Specify the decision before the data
Define the timing or information trigger, analyses, boundaries, permitted adaptations, and decision authority. Distinguish a formally planned adaptation from an operational adjustment that does not alter the statistical design. Explain how the design addresses error rates and estimation where relevant.
For a hypothetical efficacy interim, the trigger may depend on events rather than the number enrolled. Verify that the event count represents the intended information and that relevant endpoint data are sufficiently mature for the planned decision.
2. Evaluate operating characteristics
Where the design requires simulation, document scenarios, assumptions, code, random seeds, and performance measures. Include unfavorable and boundary conditions rather than only the scenario used for planning. Simulation is an implemented analysis that needs review, not a decorative appendix.
ICH E9(R1) is relevant to the treatment-effect question. Ensure that an adaptation does not leave the team unclear about what effect is being estimated or which population the final result concerns.
3. Control who sees what
Define access to unblinded interim results and the information communicated to the continuing trial team. Even a summary recommendation can reveal information if its wording or timing is not considered carefully. Plan communication with the appropriate independent oversight structure.
ICH E6(R3) provides a broader oversight reference. Our recommendation is to rehearse the workflow using synthetic data, including secure delivery, review, decision documentation, and communication boundaries.
4. Preserve the decision record
Retain the exact data cut, analysis package, review materials, decision, and authorized communications. If data are corrected after the interim, record the correction and evaluate its consequence through the approved process. Do not overwrite the evidence on which the decision was made.
A dry run should test both statistical calculations and operational execution. Confirm that an authorized reviewer can reproduce the package and that restricted information does not enter routine study materials.
Adaptive flexibility depends on disciplined preparation. The aim is to make a planned decision possible while protecting the validity and interpretability of the continuing trial, rather than treating an interim analysis as an ordinary refresh of a dashboard.
